[1]张赛锋,王道仁,邵国良.小粒径载药微球在肝细胞癌治疗中的安全性和疗效分析[J].介入放射学杂志,2024,33(12):1373-1377.
　ZHANG Saifeng,WANG Daoren,SHAO Guoliang..Small-size drug-eluting beads TACE for the treatment of hepatocellular carcinoma：its safety and efficacy analysis[J].journal interventional radiology,2024,33(12):1373-1377.
点击复制

小粒径载药微球在肝细胞癌治疗中的安全性和疗效分析()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年12
页码:
1373-1377
栏目:
综述
出版日期:
2024-12-25

文章信息/Info

Title:
Small-size drug-eluting beads TACE for the treatment of hepatocellular carcinoma：its safety and efficacy analysis
作者:
张赛锋; 王道仁; 邵国良
Author(s):
ZHANG Saifeng; WANG Daoren; SHAO Guoliang.
Department of Radiology，Tiantai County People′s Hospital （Tiantai Branch of Zhejiang Provincial People′s Hospital），Hangzhou，Zhejiang Province 310053，China
关键词:
【关键词】肝细胞癌; 载药微球; 经导管动脉化疗栓塞术
文献标志码:
A
摘要:
【摘要】肝细胞癌（HCC）是全球最常见恶性肿瘤之一，经导管动脉化疗栓塞术（TACE）是治疗中晚期HCC重要方法。目前药物洗脱微球TACE（DEB-TACE）广泛应用于HCC治疗，并研究开发出不同品牌、不同大小载药微球。临床应用中根据肿瘤大小、血供情况选择载药微球粒径大小，一般推荐粒径为＜300 μm，目前较多选择粒径为100～300 μm，更小粒径载药微球近年开始应用。该文就小粒径载药微球（＜150 μm）有效性和安全性进行综述，以期为临床治疗提供参考。

参考文献/References:

［1］Wang F，Fan J，Zhang Z，et al.The global burden of liver disease：the major impact of China［J］.Hepatology，2014，60：2099-2108.
［2］Sung H，Ferlay J，Siegel RL，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71：209-249.
［3］中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南（2022年版）［J］.肿瘤综合治疗电子杂志，2022，8：16-53.
［4］Sottani C，Poggi G，Quaretti P，et al.Serum pharmacokinetics in patients treated with transarterial chemoembolization （TACE） using two types of epirubicin-loaded microspheres［J］.Anticancer Res，2012，32：1769-1774.
［5］Melchiorre F，Patella F，Pescatori L，et al.DEB-TACE：a standard review［J］.Future Oncol，2018，14：2969-2984.
［6］Poon RT，Tso WK，Pang RW，et al.A phase Ⅰ/Ⅱ trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead［J］.Clin Gastroenterol Hepatol，2007，5：1100-1108.
［7］中国医师协会介入医师分会临床诊疗指南专委会.中国肝细胞癌经动脉化疗栓塞（TACE）治疗临床实践指南（2023年版）［J］.中华医学杂志，2023，103：2674-2694.
［8］Lammer J，Malagari K，Vogl T，et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma：results of the PRECISION V study［J］.Cardiovasc Intervent Radiol，2010，33：41-52.
［9］龚元川，邵国良.载药微球的理化特性及其在肝癌介入治疗中的应用进展［J］.介入放射学杂志，2022，31：616-622.
［10］Chang Y，Jeong SW，Young JJ，et al.Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma［J］.Int J Mol Sci，2020，21：8165.
［11］王宁，刘硕，杨雷，等.2018全球癌症统计报告解读［J］.肿瘤综合治疗电子杂志，2019，5：87-97.
［12］Namur J，Citron SJ，Sellers MT，et al.Embolization of hepatocellular carcinoma with drug-eluting beads：doxorubicin tissue concentration and distribution in patient liver explants［J］.J Hepatol，2011，55：1332-1338.
［13］Razi M，Gu JP，Xu H，et al.Conventional versus drug-eluting bead transarterial chemoembolization：a better option for treatment of unresectable hepatocellular carcinoma［J］.J Interv Med，2021，4：11-14.
［14］中国医师协会介入医师分会介入药物专业组.原发性肝细胞癌经动脉内用药与联合用药中国专家共识［J］.中华内科杂志，2023，62：785-801.
［15］Zhang S，Huang C，Li Z，et al.Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers［J］.Drug Deliv，2017，24：1011-1017.
［16］Dreher MR，Sharma KV，Woods DL，et al.Radiopaque drug-eluting beads for transcatheter embolotherapy：experimental study of drug penetration and coverage in swine［J］.J Vasc Interv Radiol，2012，23：257-64.
［17］Gholamrezanezhad A，Mirpour S，Geschwind JF，et al.Evaluation of 70-150 μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model［J］.Eur Radiol，2016，26：3474-3482.
［18］Martin R，Irurzun J，Munchart J，et al.Optimal technique and response of doxorubicin beads in hepatocellular cancer：bead size and dose［J］.Korean J Hepatol，2011，17：51-60.
［19］Padia SA，Shivaram G，Bastawrous S，et al.Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma：comparison of small-versus medium-size particles［J］.J Vasc Interv Radiol，2013，24：301-306.
［20］Joskin J，de Baere T，Auperin A，et al.Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor［J］.Cardiovasc Intervent Radiol，2015，38：372-380.
［21］Yang H，Liu GJ，Lu MD，et al.Evaluation of the vascular architecture of hepatocellular carcinoma by micro flow imaging：pathologic correlation［J］.J Ultrasound Med，2007，26：461-467.
［22］Guiu B，Schmitt A，Reinhardt S，et al.Idarubicin-loaded ONCOZENE drug-eluting embolic agents for chemoembolization of hepatocellular carcinoma：in vitro loading and release and in vivo pharmacokinetics［J］.J Vasc Interv Radiol，2015，26：262-270.
［23］Spreafico C，Cascella T，Facciorusso A，et al.Transarterial chemoembolization forhepatocellular carcinoma with a new Generation of beads：clinical-radiological outcomes and safety profile［J］.Cardiovasc Intervent Radiol，2015，38：129-134.
［24］Deipolyi AR，Oklu R，Al-Ansari S，et al.Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma［J］.J Vasc Interv Radiol，2015，26：516-522.
［25］Cura M，Heithaus E.Efficacy and safety of transarterial chemoembolization with 70-to 150-μm drug-eluting beads alone or in combination with 100-to 300-μm drug-eluting beads［J］.Proc （Bayl Univ Med Cent），2018，31：428-431.
［26］Huo Y，Xiang H，Chan M，et al.Tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma［J］.J Med Imaging Radiat Oncol，2019，63：802-811.
［27］Ballt HT，Aikimbaev K.Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns：assessment of efficacy and safety［J］.Diagn Interv Radiol，2020，26：482-487.
［28］Sakamoto I，Iwanaga S，Nagaoki K，et al.Intrahepatic biloma formation （bile duct necrosis） after transcatheter arterial chemoembolization［J］.AJR Am J Roentgenol，2003，181：79-87.
［29］朱孟超，张庆桥，徐浩，等.CalliSpheres载药微球治疗原发性肝癌并发肝脓肿4例分析［J］.介入放射学杂志，2020，29：939-941.
［30］Lewis AL，Caine M，Garcia P，et al.Handling and performance characteristics of a new small caliber radiopaque embolic microsphere［J］.J Biomed Mater Res B Appl Biomater，2020，108：2878-2888.
［31］Malagari K，Pomoni M，Spyridopoulos TN，et al.Safety profile of sequential transcatheter chemoembolization with DC BeadTM：results of 237 hepatocellular carcinoma （HCC） patients［J］.Cardiovasc Intervent Radiol，2011，34：774-785.
［32］Song MJ，Chun HJ，Song DS，et al.Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma［J］.J Hepatol，2012，57：1244-1250.
［33］Yi JW，Hong HP，Kim MS，et al.Comparison of clinical efficacy and safety between 70-150 μm and 100-300 μm doxorubicindrug-eluting bead transarterial chemoembolization for hepatocellular carcinoma［J］.Life （Basel），2022，12：297.
［34］张雯，周永杰，颜志平.再论精细TACE［J］.介入放射学杂志，2021，30：971-975.
［35］宋震，李园园，王文刚，等.TACE联合酪氨酸激酶抑制剂和卡瑞利珠单抗对中晚期肝癌的疗效与安全性［J］.介入放射学杂志，2023，32：549-553.
［36］古善智，黄满平，谭玉林，等.多纳非尼片联合抗PD-1单抗和经导管动脉化疗栓塞术治疗不可手术切除的肝细胞癌的临床研究［J］.临床肿瘤学杂志，2023，28：609-614.
［37］于士龙，刘东辉，王储，等.TACE联合卡瑞利珠单抗治疗中晚期肝细胞癌［J］.中国介入影像与治疗学，2022，19：391-395.

相似文献/References:

[1]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(12):543.
[2]王惠文,刘瑞宝,李晓婧,等.载药微球-TACE治疗难治性妇科恶性肿瘤肝转移12例[J].介入放射学杂志,2021,30(06):568.
　WANG Huiwen,LIU Ruibao,LI Xiaojing,et al.Drug- eluting beads - TACE for the treatment of refractory liver metastases from synecological malignant tumors： preliminary results in 12 patients[J].journal interventional radiology,2021,30(12):568.
[3]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(12):55.
[4]曹莉明,张勇学,梁志会,等.载药微球栓塞治疗传统TACE抵抗的原发性肝癌临床疗效[J].介入放射学杂志,2023,32(01):59.
　CAO Liming,ZHANG Yongxue,LIANG Zhihui,et al.Drug-eluting beads-trancatheter arterial chemoembolization for the treatment of hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization: observation of its clinical effect[J].journal interventional radiology,2023,32(12):59.
[5]李坤峰,郑　睿,胡章明.CalliSpheres载药栓塞微球加载表柔比星治疗不可切除原发性肝癌的疗效[J].介入放射学杂志,2023,32(02):131.
　LI Kunfeng,ZHENG Rui,HU Zhangming..Clinical efficacy of CalliSpheres drug-eluting beads loaded with epirubicin in the treatment of unresectable primary liver cancer[J].journal interventional radiology,2023,32(12):131.
[6]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(12):36.
[7]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(12):90.
[8]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):921.
[9]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):968.
[10]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(12):995.

备注/Memo

备注/Memo:
（收稿日期：2024-01-12）
（本文编辑：谷珂）
更新日期/Last Update: 2024-12-18